MaxCyte, Inc. · NASDAQ:MXCT
MaxCyte — Merger or Acquisition (November 2026)
14 slides from MaxCyte's merger presentation, Nov 10, 2026
Slide 1: MaxCyte to Acquire Akron Bio
are trademarks of MaxCyte, Inc. in the U.S.A. MaxCyte to Acquire Akron Bio November 10, 2026 © 2026 MaxCyte, Inc. All Rights Reserved
Slide 2: Forward-Looking Statement Disclaimer
Forward-Looking Statement Disclaimer 2 © 2026 MaxCyte, Inc. All Rights Reserved Certain statements in this document (this “Presentation”) are, or may be deemed to be, forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995
Slide 3: MaxCyte Continues to Strengthen Operationally and Financially
3 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte Continues to Strengthen Operationally and Financially ✓ Delivered a strong third quarter as MaxCyte continues to execute – Total revenue of $10.2M (+49% YoY); core revenue of $8.2M (+27% YoY) – PA revenue +20% YoY; gross margin of 83% (80% non-GAAP
Slide 4: MaxCyte to Acquire Akron Bio: Deal Overview
4 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing Deal Overview ACQUISITION DETAILS ✓ Following a competitive process, we have signed a definitive agreement to acquire Akron Bio from Arcline ✓ Akron attracted multiple i
Slide 5: Why Akron Bio: Four Ways the Combination Creates Value
© 2026 MaxCyte, Inc. All Rights Reserved 5 Why Akron Bio: Four Ways the Combination Creates Value Strengthened Leadership in Cell Therapy 3x MaxCyte triples its commercial & registrational programs ( 4 → 12), including 5 approved therapies Cross-Selling Opportunity 2x Addressable program base, with
Slide 6: Akron Bio is a Leading Supplier of Critical Cell Therapy Inputs
6 © 2026 MaxCyte, Inc. All Rights Reserved Akron Bio is a Leading Supplier of Critical Cell Therapy Inputs Headquartered in Boca Raton, FL Founded in 2006 cGMP production facility and support from a network of global cGMP contract manufacturing partners Revenue ($M)(2) Akron Highlights ✓ Mission-cri
Slide 7: MaxCyte and Akron Are Embedded Across Complementary Steps of the Workflow
© 2026 MaxCyte, Inc. All Rights Reserved 7 Process Development Cell Isolation & Expansion Cell Culture Cell Engineering Cell Expansion Cryopreservation USED BEFORE CELL ENGINEERING USED AFTER CELL ENGINEERING Expanding Our Footprint Across the Cell Therapy Workflow and Developers’ Regulatory Package
Slide 8: Expanded Portfolio Covers the Development Lifecycle
8 © 2026 MaxCyte, Inc. All Rights Reserved Expanded Portfolio Covers the Development Lifecycle, Pairing MaxCyte’s Platform Economics With Akron Bio’s Recurring Consumables Razor/Razor Blade Economics Full scale RUO Instrument Sale Annual License Fee Razor/Razor Blade Economics + Share of Therapeutic
Slide 9: Broad Combined Clinical Portfolio Underpins 12 Commercial and Registrational-Stage Programs
© 2026 MaxCyte, Inc. All Rights Reserved 9 1 MaxCyte +4 Akron 5 Commercial Programs +3 MaxCyte Registrational Programs +4 Akron Registrational Programs 12 Commercial + Registrational Programs Broader portfolio with multiple near-term commercialization opportunities Established Commercial Base MaxCyt
Slide 10: Akron Bio More Than Doubles Our Addressable Program Base
© 2026 MaxCyte, Inc. All Rights Reserved 10 Akron Bio More Than Doubles Our Addressable Program Base within the Growing Cell Therapy Market ~770 ~360 Combined company MaxCyte today Attractive & Growing Cell Therapy Market Worldwide Commercial Cell Therapy Revenue Forecast ($B)(1) Addressable Ex Vivo
Slide 11: MaxCyte 2.0 - Akron Bio Strengthens Our Growth Story
© 2026 MaxCyte, Inc. All Rights Reserved 11 MaxCyte 2.0 - Akron Bio Strengthens Our Growth Story and Accelerates Our Path to Profitability Strengthened Leadership in Cell Therapy ✓ Triples commercial & registrational programs to 12 including 5 commercial therapies ✓ Spec’d into 100+ clinical cell th
Slide 12: Thank you! Any Questions?
All other trademarks are the property of their respective owners. ©2025 MaxCyte, Inc. All rights reserved. For a complete list of MaxCyte trademarks in the United States and other countries, please visit maxcyte.com/trademarks. Thank you! Any Questions? ir@maxcyte.com 12 © 2026 MaxCyte, Inc. All Rig
Slide 13: Appendix
Appendix 13 © 2026 MaxCyte, Inc. All Rights Reserved
Slide 14: Akron Bio Interception Point and Spec-In Along the Development Cycle
14 © 2026 MaxCyte, Inc. All Rights Reserved Discovery / R&D Preclinical Early-Stage Trials Late-Stage Trials Launched Akron Bio interception point Process development Clinical and commercial GMP manufacturing RUO- / GMP-grade GMP-grade Ancillary inputs may be interchanged as customers define workflo